Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center
Executive Summary
Lion Biotechnologies Inc. (cancer immunotherapies) licensed exclusive rights to two patent-pending tumor infiltrating lymphocyte (TIL) technologies from the University of South Florida’s H. Lee Moffitt Cancer Center & Research Institute. The license continues until the last patent related to the technologies expires, or 20 years, whichever comes first.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice